Multiple Prolactin (PRL) Receptor Cytoplasmic Residues and Stat1 Mediate PRL Signaling to the Interferon Regulatory Factor-1 Promoter
Yu-fen Wang,
Kevin D. ONeal and
Li-yuan Yu-Lee
Department of Medicine (Y.-f.W., L.-y.Y.-L.) Department of
Microbiology and Immunology (K.D.O., L.-y.Y.-L.) Department of Cell
Biology (L.-y.Y.-L.) Baylor College of Medicine Houston, Texas
77030
 |
ABSTRACT
|
---|
The Nb2 PRL receptor (PRL-R) is known to mediate
PRL signaling to the interferon (IFN) regulatory factor-1 (IRF-1) gene
via the family of signal transducers and activators of transcription or
Stats. To analyze the components of the PRL-R/Stat/IRF-1 signaling
pathway, various PRL-R, Stat, and IRF-1-CAT reporter constructs were
transiently cotransfected into COS cells. First, mutations in the
IFN
-activated sequence (GAS), either multimerized or in the context
of the 1.7-kb IRF-1 promoter, failed to mediate a PRL response, showing
that the IRF-1 GAS is a target of PRL signaling. Next, pairwise alanine
substitutions into conserved residues in the proline-rich motif or Box
1 region and two tyrosine mutations, Y308F and Y382F, in the PRL-R
intracellular domain all impaired PRL signaling to multimerized GAS or
to the 1.7-kb IRF-1 promoter. Furthermore, these PRL-R mutants mediated
reduced Stat1 binding to the IRF-1 GAS. Transfection of Stat1 further
enhanced PRL signaling to the IRF-1 promoter, suggesting that Stat1 is
a positive mediator of PRL action. These studies show that both
membrane proximal and distal residues of the PRL-R are involved in
signaling to the IRF-1 gene. Further, Stat1 and the GAS element are
important for PRL activation of the IRF-1 gene.
 |
INTRODUCTION
|
---|
PRL is a pituitary peptide hormone and a cytokine that exerts
pleiotropic actions on a wide range of cell types and tissues (1, 2, 3).
PRL stimulates the growth and differentiation of cells within the
mammary gland (4), ovary (5), uterus (6), and prostate (7). PRL also
modulates the proliferative potential of T lymphocytes in the immune
system (2), exerts antiapoptotic effects on glucocorticoid-induced cell
death in lymphocytes (8), and may be involved in adipocyte
differentiation in the bone marrow stroma (9). Thus, PRL action depends
on the cell type and its stage of differentiation in the target tissue.
These pleiotropic actions of PRL are mediated by the PRL receptor
(PRL-R), which is a member of the hematopoietin/cytokine receptor
superfamily (10, 11). Three PRL-R forms have been identified, the
short, Nb2, and long PRL-R, which differ in the length and sequence of
the intracellular cytoplasmic domain. This is a result of either
alternative splicing of 3'-end exons to generate the short PRL-R (12)
or an in-frame truncation relative to the long PRL-R to generate the
Nb2 T cell PRL-R (13, 14). Interestingly, both the Nb2 and long PRL-R
are capable of mediating lactogenic and mitogenic signals (14, 15, 16),
whereas the function of the short PRL-R is less clear (14, 15, 17).
PRL-R signal transduction follows the JAK/Stat signaling pathway that
is generally used by all of the hematopoietin/cytokine receptors (18).
PRL binding to PRL-R leads to receptor dimerization or oligomerization
(19, 20, 21), which activates PRL-R-associated JAK2 protein tyrosine
kinases (reviewed in Refs. 2, 19). Activated JAK2 further
phosphorylates downstream target proteins, which include the PRL-R
intracellular domain (22). Phosphorylated tyrosine residues within the
PRL-R intracellular domain are thought to provide docking sites for the
recruitment of signaling proteins containing Src homology 2 (SH2)
domains (23). These include a family of preexisting cytoplasmic factors
collectively called signal transducers and activators of transcription,
or Stats (18). Tyrosine-phosphorylated Stats form homo- or
heterocomplexes, translocate into the nucleus, bind to cognate DNA
elements, and turn on target genes (2, 18). PRL stimulates the
activation of Stat1, Stat3, Stat5a, and Stat5b (24, 25, 26, 27), and various
Stat combinations are used to activate PRL-inducible target promoters,
including those for the differentiation-specific genes ß-casein (25, 28), ß-lactoglobulin (29), whey acidic protein (30), and
2-macroglobulin (31), and a growth-related gene
interferon-regulatory factor-1 (IRF-1) (32, 33). Interestingly, the
initial PRL-R/JAK/Stat signaling pathway involves many of the same
molecules, but the final biological outcome of PRL-R signaling depends
on the presence of various cytoplasmic as well as nuclear factors, the
promoter context of the target gene, and the stage of development of
the responding cell.
Details of PRL-R signal transduction have been elucidated by
mutagenesis of the PRL-R. The cytoplasmic membrane-proximal
proline-rich motif (PRM) (34) or Box 1 region of the PRL-R consists of
a highly conserved eight-amino acid sequence,
aliphatic-aromatic-proline-X-aliphatic-proline-x-proline
(Ile-Phe-Pro-Pro-Val-Pro-Gly-Pro), which is critical for receptor
signaling as it mediates interaction with the JAK2 kinase (35, 36).
PRM/Box 1 mutations prevent phosphorylation of the PRL-R as well as
activation of the ß-casein promoter (36). Mutations or deletions of
various tyrosine residues in the context of the Nb2 PRL-R showed that a
single carboxy-terminal tyrosine residue Y382 is important for
activating the ß-casein promoter (22). However, in promyeloid cells,
PRL-R Y382 does not appear to be necessary for activating Stat1, Stat3,
and Stat5 (24) or for mediating cell proliferation (35). Thus, in
addition to the PRM/Box 1 region, which is critical for PRL-R
activation, the carboxy terminus of the PRL-R appears to be important
for mediating a differentiation signal, whereas a different region is
needed for mediating a proliferative signal.
To address PRL-inducible signaling mechanisms, the IRF-1 gene has been
analyzed extensively, as it is an immediate early gene that is
transcriptionally regulated by PRL stimulation in a PRL-dependent T
cell line, Nb2 (37, 38, 39, 40). Furthermore, both IRF-1 promoter-proximal and
-distal elements are involved in cooperative interactions in responding
to PRL stimulation (32, 40). In particular, the promoter-proximal
interferon
-activated sequence (GAS) element has been shown to be a
PRL-inducible enhancer when placed in reverse orientation upstream of
the heterologous thymidine kinase (TK) promoter (32). However, a role
of GAS in mediating a PRL response in the context of the native 1.7-kb
IRF-1 promoter has not been examined. Electrophoretic mobility shift
assays (EMSA) have shown that both Stat1 (32, 33, 41, 42) and Stat5
(27, 42, 43) interact with the IRF-1 GAS in a PRL-inducible manner.
Surprisingly, overexpression of transfected Stat5a or Stat5b, two
closely related but distinct Stat5 genes (25, 26, 27, 44), inhibits PRL
induction of the IRF-1 promoter when cotransfected with the PRL-R and
1.7-kb IRF-1-CAT reporter constructs into COS cells (27). The
functional significance of exogenous expression of Stat1 at the IRF-1
promoter has not been examined. In this manuscript, the relative
importance of PRL-R intracellular domains, Stat1, and IRF-1 GAS element
in mediating PRL signaling to the IRF-1 gene was examined by mutational
analysis. Our results show that the PRM/Box 1 and two tyrosine residues
in the Nb2 PRL-R are involved in PRL signaling to the IRF-1 gene.
Further, Stat1 is an important positive mediator of PRL signaling to
the GAS element in the IRF-1 promoter.
 |
RESULTS
|
---|
IRF-1 GAS is a PRL-Responsive Element
Previous studies have shown that the 1.7-kb IRF-1 promoter is
responsive to PRL stimulation (40), and deletion analyses have
localized a minimal PRL-responsive region from -136 bp to -112 bp
(32). Within this region lies a 11-bp GAS core element, TTTCCCCGAAA,
which when placed in reverse orientation in front of a heterologous TK
promoter mediated PRL induction (32), demonstrating that GAS alone
mediates a PRL response. Mutations were introduced three at a time
across the GAS sequence and tested for their ability to inhibit
PRL-inducible nuclear factor binding (see Materials and
Methods). The results suggest that the 5'-half of the GAS
palindrome (TTT) is critical but that the rest of the GAS element is
also involved in PRL-inducible protein/DNA interactions (data not
shown). Based on the mutagenesis results, mutations were introduced
into the entire 11-bp GAS element. Three copies of either wild type GAS
(3C WT GAS) or mutant GAS (3C MT GAS) were synthesized and cloned in
the sense orientation into the heterologous TK promoter pBLCAT3
reporter (45). These constructs were transiently cotransfected with the
Nb2 PRL-R into COS cells and stimulated with PRL for 24 h (Fig. 1A
). The COS cell system has been successfully used to
analyze PRL signaling to both the IRF-1 and milk protein gene promoters
(26, 27, 46). 3C WT GAS mediated a 25-fold induction of the
chloramphenicol acetyltransferase (CAT) reporter gene in response to
PRL stimulation, whereas the mutant GAS construct failed to respond to
PRL stimulation.

View larger version (20K):
[in this window]
[in a new window]
|
Figure 1. IRF-1 GAS Is a PRL-Responsive Element
A, 3C GAS-TK-CAT. Multimerized (three copies) of the WT GAS or MT GAS
(see Materials and Methods) were cloned in the sense
orientation into the TK-CAT vector (0.3 µg) which was transiently
cotransfected into COS cells along with the Nb2 PRL-R construct (1.0
µg). PRL-inducible CAT enzyme activity was measured after 24 h
of PRL treatment. Error bar, SEM of three independent
experiments. B, 1.7-kb IRF-1-CAT. The single GAS element in the 1.7-kb
IRF-1 promoter was mutated by PCR-based mutagenesis (see
Materials and Methods). WT and MT 1.7-kb IRF-1-CAT were
tested for their ability to respond to PRL stimulation as described in
panel A. Error bar, average of two experiments.
Inset, one representative set of CAT data showing the
1-, and 3-acetylated [14C]chloramphenicol levels in the
corresponding WT and MT 1.7-kb IRF-1-CAT-transfected cells. Open
bar, -PRL; closed bar, +PRL.
|
|
To further define whether the GAS element plays an important role in
mediating the PRL response in the context of the 1.7-kb IRF-1 promoter,
the same mutations as above were introduced into the GAS core by
overlap-extension PCR mutagenesis (47) (see Materials and
Methods). The ability of the 1.7-kb IRF-1 promoter vs.
the mutant 1.7-kb IRF-1 promoter that contains a mutated GAS core to
respond to PRL stimulation was examined (Fig. 1B
). As previously
observed, PRL stimulated a 3-fold induction in 1.7-kb IRF-1-CAT
expression, with significant levels of basal CAT expression in
unstimulated cells (27). In contrast, the 1.7-kb IRF-1 promoter that
contains a mutant GAS was no longer responsive to PRL stimulation, and
the basal activity of the mutant promoter was also reduced. These
results confirm that GAS element alone is not only a PRL-responsive
element but that it is also a critical element for mediating the PRL
responsiveness of the native 1.7-kb IRF-1 promoter.
PRM/Box 1 of the PRL-R Is Required for PRL Induction of the IRF-1
Gene
Our data show that both the 3C GAS-TK-CAT and the 1.7-kb IRF-1-CAT
mediated a response to PRL stimulation; therefore, both CAT constructs
are useful as targets for assessing PRL-R-mediated signaling events.
Previously, a membrane-proximal PRM/Box 1 motif, a highly conserved
domain in the hematopoietin/cytokine receptors (34), has been shown to
be important for signaling from the PRL-R to various milk protein gene
promoters (36, 48). However, its importance for signaling to the
growth-related IRF-1 promoter has not been examined. Based on the
conserved residues, Ile-Phe-Pro-Pro-Val-Pro-Gly-Pro
(IFP1PVP2GP3), pair-wise double
alanine substitutions were introduced into the eight amino acids (a.a.)
PRM/Box 1 by overlap-extension PCR mutagenesis (47). Three PRM/Box 1
mutants, containing alanine replacements of the FV, P1P2, or P2P3
residues in the context of the Nb2 PRL-R, were generated (Fig. 2A
). COS cells were transiently transfected with the
wild type and mutant PRM/Box 1 PRL-R constructs, stimulated with PRL
for 24 h, and examined for PRL-R expression. Western blot analysis
employing a polyclonal rabbit anti-PRL-R peptide antibody (Ab) was
performed to show that all of the mutant PRL-R transfectants expressed
the 62-kDa Nb2 PRL-R protein to similar levels as the wild type PRL-R
(Fig. 2B
, lanes 38 vs. lanes 1 and 2). No PRL-R was
detected in parental COS cells or cells transfected with empty pECE
expression vector (data not shown).

View larger version (31K):
[in this window]
[in a new window]
|
Figure 2. Mutations in the PRM/Box 1 Inhibit PRL-R Signaling
to the IRF-1 Promoter
A, Diagram of the PRM/Box 1 and tyrosine mutations in the Nb2 PRL-R.
Double alanine substitutions were introduced into the highly-conserved
FV and P residues as indicated (see Materials and
Methods), generating FV, P1P2, and P2P3 Nb2 PRL-R mutants. The
three tyrosine residues in the cytoplasmic domain of the Nb2 PRL-R are
as indicated. Y309 and Y382 were mutated to phenylalanine, generating a
Y309F and a Y382F Nb2 PRL-R mutant. TM, Transmembrane domain; N, amino
terminus; C, carboxy terminus of the Nb2 PRL-R. B, Expression of mutant
Nb2 PRL-Rs. Membrane fractions of PRL-R cDNA-transfected COS cells were
solubilized for Western blot analysis using anti-PRL-R peptide
polyclonal antibodies (R123) followed by ECL. A single band
corresponding to the 62-kDa Nb2 PRL-R (arrow) was
observed in each PRL-R transfectant. C, 1.7 kb IRF-1-CAT. Wt or PRM/Box
1 mutant Nb2 PRL-R constructs were cotransfected with 1.7 kb IRF-1-CAT
into COS cells and assayed for PRL inducibility as described in Fig. 1 .
D, 3C GAS-TK-CAT. Same protocol was used as in panel C except that 3C
GAS-TK-CAT was used as the read out. Open bar, -PRL;
closed bar, +PRL. Error bar,
SEM of three independent experiments.
|
|
Next, the ability of the PRM mutant PRL-Rs to signal to the IRF-1
promoter was examined by cotransfection with either the 1.7-kb
IRF-1-CAT or 3C GAS-TK-CAT into COS cells. Wild type PRL-R mediated a
3-fold PRL induction of the 1.7-kb IRF-1 promoter as expected (see also
Fig. 1B
), but all three PRM mutant PRL-Rs failed to mediate PRL
stimulation of the 1.7-kb IRF-1 promoter (Fig. 2C
). Similarly, wild
type PRL-R mediated about 10-fold induction of the multimerized IRF-1
GAS element (Fig. 2D
). Interestingly, the FV and the P1P2 mutations
severely reduced, but did not abrogate, mutant PRL-R signaling to the
GAS element, whereas the P2P3 mutant PRL-R again failed to activate the
GAS. These results show that the PRM/Box 1 is critical for
PRL-R-mediated signaling to either the IRF-1 GAS element or the
full-length IRF-1 promoter.
PRL-R Y309 and Y382 Are Required for Signaling to the IRF-1
Promoter
In addition to the PRM/Box 1 region, the Nb2 PRL-R contains three
tyrosine residues in the intracellular domain. Y237 is only two a.a.
inside the transmembrane domain and does not appear to be involved in
PRL-R phosphorylation or signaling to the ß-casein promoter (22).
Mutational analysis has shown that only the most carboxy Y382 residue
is required for PRL-R signaling to the ß-casein promoter in 293
cells. Which tyrosine residues are involved in signaling to the IRF-1
promoter is not known. To address this, two PRL-R tyrosine mutant
constructs, Y309F and Y382F (Tyr to Phe mutation) (Fig. 2A
), were
transiently cotransfected into COS cells with either the 1.7-kb
IRF-1-CAT (Fig. 3A
) or 3C GAS-TK-CAT (Fig. 3B
)
constructs. Basal PRL-R activity did not change in the presence of
mutant PRL-Rs. However, both Y309F and Y382F PRL-R mutants were reduced
in their ability to signal to either promoter in response to PRL
stimulation. Both Y309F and Y3882F mutant PRL-Rs mediated only about
30%40% of wild type PRL-R activity in response to PRL stimulation
(Fig. 3
, A and B). These results show that both Y309 and Y382 in the
PRL-R are also important for signaling to the IRF-1 promoter, in
contrast to the results observed with the ß-casein promoter (22).

View larger version (17K):
[in this window]
[in a new window]
|
Figure 3. Impaired Signaling of Nb2 PRL-R Tyrosine Mutants to
the IRF-1 Promoter
Wt, Y309F, or Y382F Nb2 PRL-R constructs (see diagram in
Fig. 2A ) were cotransfected with 1.7-kb IRF-1-CAT (A) or 3C GAS-TK-CAT
(B) into COS cells and assayed for PRL inducibility as described in
Fig. 1 . Open bar, -PRL; closed bar,
+PRL. Error bar, SEM of three independent
experiments.
|
|
Mutant PRM/Box 1 and Tyrosine PRL-Rs Fail to Activate Stat1
PRL signaling to either 1.7-kb IRF-1 promoter or multimerized
IRF-1 GAS is likely mediated through the activation of endogenous Stat
factors in COS cells. To assess which Stat factors may be involved, the
wild type PRL-R construct was transiently transfected into COS cells,
and at 24 h posttransfection, cells were stimulated with PRL for
30 min. Whole-cell extracts were prepared and analyzed by EMSA using a
32P-labeled 32-bp IRF-1 GAS oligo as probe (Fig. 4A
). In COS cell extracts, PRL stimulated the formation
of one complex (arrow) at the IRF-1 GAS (Fig. 4A
, lanes 1
and 2). The various slower and faster migrating bands in each lane were
nonspecific and were not further analyzed. This PRL-inducible
complex contains Stat1, as it can be supershifted (asterisk)
by increasing concentrations of anti-Stat1 monoclonal antibodies (mAb)
(Fig. 4A
, lanes 3 and 4) and by a pan-Stat polyclonal Ab (Fig. 4A
, lanes 5 and 6), which recognizes the conserved amino terminus of Stat
factors (49), but not by anti-Stat3 mAb (Fig. 4A
, lanes 7 and 8). The
differences in the anti-Stat1 vs. anti-pan-Stat antibody
supershifted bands are likely due to differences in the
monoclonal vs. polyclonal Abs used. Further, the
PRL-inducible complex was specific as it can be competed by increasing
concentrations of cold GAS oligo (Fig. 4A
, lanes 911), but not by an
unrelated DR1 oligo representing the chicken ovalbumin upstream
promoter (COUP) transcription factor-binding site (Fig. 4A
, lanes
1214) (33). The EMSA results clearly show that wild type Nb2 PRL-R
activates endogenous Stat1 to bind to the IRF-1 GAS in a PRL-inducible
manner in PRL-R-transfected COS cells.

View larger version (80K):
[in this window]
[in a new window]
|
Figure 4. PRL-R Mediates PRL-Inducible Stat1 Binding to the
IRF-1 GAS
A, PRL induces Stat1 binding to the IRF-1 GAS. Whole cell extracts from
control (lane 1) and PRL-stimulated (lanes 214) COS cells, which have
been transiently transfected with the Nb2 PRL-R construct, were used in
EMSA with an IRF-1 GAS oligo. The PRL-inducible complex
(arrow) was supershifted (asterisk) with
anti-Stat1 mAb (lanes 3 and 4) and with anti-pan-Stat polyclonal Ab
(lanes 5 and 6), but not with anti-Stat3 mAb (lanes 7 and 8) in 1:20
and 1:10 dilutions. The specificity of the PRL-inducible complex was
determined by competition with excess cold GAS oligo (lanes 911) or
an unrelated DR1 oligo (lanes 1214) in 10x, 20x and 50x molar
concentrations. B, PRL-R mediates Stat1 binding to the IRF-1 GAS. Whole
cell extracts from control or PRL-stimulated COS cells transfected with
either control vector alone (lanes 1 and 2), or constructs containing
wild type Nb2 PRL-R (lanes 3 and 4), mutant P2P3 Nb2 PRL-R (lanes 5 and
6), mutant Y309F Nb2 PRL-R (lanes 7 and 8), or mutant Y382F Nb2 PRL-R
(lanes 9 and 10) were assayed by EMSA with an IRF-1 GAS oligo.
Arrow, PRL inducible Stat1 complex.
|
|
Because the various mutant PRL-Rs retained some ability to signal to
the IRF-1 promoter (Figs. 2
and 3
), the ability of these PRL-Rs to
activate Stat1 to bind to the IRF-1 GAS was examined. Whole-cell
extracts prepared from wild type PRL-R-transfected COS cells showed one
PRL-inducible Stat1 complex (arrow) (Fig. 4B
, lanes 3 and 4)
that was not present in empty vector transfected control cells (Fig. 4B
, lanes 1 and 2). In contrast, the inactive P2P3 PRM/Box 1 PRL-R
mutant (Fig. 2
) was unable to activate Stat1 binding to the IRF-1
promoter (Fig. 4B
, lanes 5 and 6). On the other hand, both Y309F and
Y382F PRL-R mutants, which exhibited a reduced ability to activate the
IRF-1 GAS (Fig. 3
), mediated weak Stat1 binding to the IRF-1 GAS in
response to PRL stimulation (Fig. 4B
, lanes 8 and 10). The faint
signals are difficult to discern in this experiment but are
reproducible (data not shown). These results show that Stat1 binding to
the IRF-1 GAS requires activation through the PRL-R and that the degree
of inhibition of Stat1/IRF-1 GAS interaction correlated with the
severity of the PRL-R mutations, i.e. PRM/Box 1 >
Y382 > Y309. Thus, the membrane-proximal PRM/Box 1 is critical,
but both Y309 and Y382 in the PRL-R are also involved in activating
Stat1 binding to the IRF-1 GAS.
Stat1 is a Positive Mediator in PRL Signaling to the IRF-1
Promoter
The EMSA results strongly suggest that Stat1 is an important
mediator of PRL-R signaling to the IRF-1 promoter in COS cells. To
directly assess the role of Stat1, a Stat1
expression construct was
introduced into COS cells and examined for its ability to regulate
either the 1.7-kb IRF-1 promoter or 3C GAS element. Wild type Stat1
was cloned into the pcDNA3 expression vector for high level expression
and transiently cotransfected into COS cells along with the Nb2 PRL-R
and the 1.7-kb IRF-1-CAT constructs (Fig. 5A
).
Vector-transfected control cells showed about a 2-fold induction of the
1.7-kb IRF-1 promoter. Transfected Stat1
led to a 6-fold PRL
induction of the IRF-1 promoter, suggesting that Stat1
is limiting
in the COS cells and that Stat1
is a positive mediator of PRL
signaling to the IRF-1 promoter. The higher level of PRL induction
correlated with a higher level (
2- to 3-fold) of Stat1
protein
expression in the transfected COS cells relative to the endogenous
Stat1
levels in vector-transfected control cells (Fig. 5A
, inset). Again, an enhancement of PRL induction of the 3C GAS
element was also observed in the presence of exogenous Stat1
(Fig. 5B
). These results support a role of Stat1
as a positive mediator of
PRL signaling to the IRF-1 promoter in COS cells.

View larger version (14K):
[in this window]
[in a new window]
|
Figure 5. Stat1 Mediates PRL Signaling to the IRF-1 Promoter
A pcDNA3-Stat1 construct or pcDNA3 vector alone (1 µg) was
cotransfected with the Nb2 PRL-R construct and 1.7 IRF-1-CAT (A) or 3C
GAS-TK-CAT (B) into COS cells and assayed for PRL inducibility as
described in Fig. 1 . Inset, Western blot analysis of
Stat1 protein levels in vector or Stat1-transfected COS cells.
Open bar, -PRL; closed bar, +PRL.
Error bar, SEM of three independent
experiments.
|
|
 |
DISCUSSION
|
---|
Signaling along the PRL-R/JAK/Stat1 pathway to the GAS element in
the IRF-1 gene was examined in a reconstituted COS cell system. Our
studies showed that the PRM/Box 1 region and both tyrosines, Y309 and
Y382, in the Nb2 PRL-R cytoplasmic domain are critical for signaling to
the IRF-1 promoter. Mutational analysis further demonstrated that the
IRF-1 GAS is a target of PRL signaling and that Stat1
is a positive
mediator of PRL signaling to the IRF-1 gene.
Our original observation showed that PRL stimulates IRF-1 gene
transcription in a biphasic manner, activating G1 as well as S phase
transcription of the IRF-1 gene in Nb2 T cells (32). G1 activation of
the IRF-1 gene can be mediated by a minimal promoter that contains the
GAS element, but sequences upstream of GAS are also important for
mediating G1/S transcription of the IRF-1 gene in response to PRL
stimulation (40). Mutational analysis further confirms the critical
role of the GAS as a PRL-responsive element, not only in the context of
the heterologous TK promoter (Fig. 1A
), but also in the context of the
native 1.7-kb IRF-1 promoter (Fig. 1B
). It is interesting that
mutations in the GAS element not only abolished PRL-inducible
activation of the IRF-1 promoter, but also significantly diminished the
basal activity of the 1.7-kb IRF-1 promoter. This suggests that in
addition to PRL-inducible Stat-like factors, some of the factors
interacting directly or indirectly at the GAS and surrounding sequences
may be involved in basal transcriptional activity of the IRF-1 gene.
These results support our previous observation that the GAS is required
for a PRL-inducible effect, but that interactions of factors binding to
the GAS with those interacting in promoter-distal regions are required
for full IRF-1 promoter activation by PRL and for cell cycle-regulated
expression of the IRF-1 gene (32, 39). In this context, sequences in
the entire GAS core, TTTC CCC GAAA, appear to be involved in binding
PRL-inducible nuclear factors in Nb2 T cells (data not shown). This
binding pattern is different from GAS interactions with interferon-
(IFN
)-inducible Stat1, which contacts mainly the TTC and the middle
A residues in the outer portion of the palindrome (50, 51). The broader
binding pattern is consistent with the presence of other factors in the
GAS complex in response to PRL stimulation in Nb2 T cells.
Using multimerized GAS elements or the 1.7-kb IRF-1 promoter as a
read-out, the residues within the cytoplasmic domain of the PRL-R were
examined for their role in signal transduction. The PRM/Box 1 region is
critical for PRL-R signaling, as pairwise mutations in this region
severely reduced PRL-R signaling in both transfected COS cells (Fig. 2
)
and FDC-P1 premyeloid cells (52). It is now recognized that the PRM/Box
1 region mediates interaction of the PRL-R with the JAK2 kinase (19)
and perhaps other molecules (53). Such functional interaction has also
been observed for the GH receptor (GH-R) PRM/Box 1 region and JAK2 (19, 54).
The Nb2 PRL-R contains a 198-a.a. in-frame truncation relative to the
long PRL-R and is missing an additional six tyrosine residues that are
present in the long PRL-R (13). Consequently, only three tyrosines,
Y237, Y309, and Y382, are present in the Nb2 PRL-R cytoplasmic domain.
Y237, which is only two a.a. inside of the transmembrane domain, does
not appear to be required for PRL-R functions (22). PRL-R deletions
encompassing Y309 affected neither PRL-R tyrosine phosphorylation nor
its ability to stimulate the differentiation-specific ß-casein
promoter (22, 36). Only the last Y382 appears to mediate PRL-R tyrosine
phosphorylation and signaling to the ß-casein promoter (22). In
contrast, our studies showed that both Y309 and Y382 are required to
fully activate the growth-related IRF-1 promoter or the multimerized
GAS-TK promoter (Fig. 3
). Mutations in either of the two PRL-R Y
residues inhibit Stat1 binding to the IRF-1 GAS (Fig. 4
), suggesting
that these Y residues when phosphorylated may serve as docking sites
for recruiting Stat1 (55). Recent studies have illustrated that Stat1
SH2 domain can recognize two types of phosphorylated tyrosine residues,
one in the IFN
-R at Y440DKPH (56) and one represented by the gp130
YXPQ motif (57), which is a subset of the Stat3 binding motif YXXQ in
gp130 (55). Neither Y309PGQ nor Y382LDP in the Nb2 PRL-R conform to
these two Stat1-binding motifs. However, they both contain a P residue
in the vicinity of the Y residue, and Y309PGQ could form a potential
Stat3 docking site in the PRL-R. It is interesting to note that all
three receptor systems, IFN
-R (56), interleukin-6 through gp130
(57), and PRL-R (Fig. 3
), can mediate IRF-1 promoter activation through
Stat1 recruitment, presumably via the above receptor motifs. Whether
Stat1 physically interacts at the two PRL-R Y residues is under
investigation.
A mutant Nb2 PRL-R that is deleted at residue G328, leaving intact Y309
at its truncated carboxy terminus, was still capable of inducing the
expression of the growth-related gene, ornithine decarboxylase, and
mediating mitogenesis in PRL-stimulated promyeloid 32D cells (35).
However, the extent of mitogenesis was reduced relative to the
full-length Nb2 PRL-R. This suggests that in the presence of intact
PRM/Box 1, Y309 in the Nb2 PRL-R is sufficient for Stat activation and
some mitogenic signaling (35), in agreement with our analysis that Y309
is important in mediating PRL stimulation of Stat1 (Fig. 4
) and IRF-1
promoter activation (Fig. 3
). However, recent studies showed that
phosphorylated receptor tyrosine residues may not be needed in certain
GH-R-mediated functions (58, 59). This and other observations led to
the suggestion that tyrosine residues on the JAK kinase itself may be
directly involved in recruiting and activating Stat factors (54, 60, 61). Whether JAK2 can recruit Stats in the PRL-R-signaling pathway is
not known. Our studies show that PRM/Box 1 and both Y309 and Y382
residues are involved in signaling to the growth-related IRF-1
promoter. Thus, in contrast to other cytokine receptors that utilize
distinct portions of their cytoplasmic domains for signaling for growth
vs. differentiation functions (19, 62, 63), the PRL-R Y382
appears to mediate signaling to both a growth-related and a
differentiation-specific promoter (22).
PRL activates Stat1, Stat3, Stat5a, and Stat5b tyrosine phosphorylation
and DNA-binding activity in various target cells (24, 28, 30, 31, 33, 41, 64). How these Stat factors mediate a specific PRL response depends
on the target promoter context and cell type and stage of development.
For example, PRL stimulates Stat5a to activate milk protein genes in
the mammary cells (26, 28, 30, 46) and Stat5b to activate
2-macroglobulin gene in ovarian granulosa cells (31). On the other
hand, PRL stimulates primarily Stat1 to bind to the IRF-1 GAS (32, 33)
(Fig. 4
), and Stat1 functionally activates the IRF-1 promoter in
response to PRL stimulation (Fig. 5
). Interestingly, a dominant
negative Stat1 mutant (Y701F), which has been shown to inhibit IFN
signaling (65), only partially (2030%) inhibited endogenous Stat1
activation of the IRF-1 promoter in response to PRL stimulation in
transfected COS cells (data not shown). These results suggest that
other factors, in addition to Stat1, also play a role in PRL regulation
of the IRF-1 promoter.
PRL also stimulates Stat5a and Stat5b to bind to the IRF-1 promoter
(33), but surprisingly, this interaction leads to an inhibition by
Stat5a as well as Stat5b of PRL induction of the IRF-1 promoter in
transfected COS cells (27). Our data further show that inhibition by
Stat5b does not require direct DNA binding, but most likely involves
squelching (66) by Stat5b of a factor that Stat1 needs to stimulate the
IRF-1 promoter (27). The relative kinetics of Stat1 vs.
Stat5 induction by PRL and the mechanism underlying the antagonism
between Stat1 vs. Stat5 at the IRF-1 promoter are under
investigation. Thus, PRL can utilize different Stat factors to activate
or repress gene transcription in a promoter-specific manner.
Interestingly, PRL can stimulate Stat1, Stat3, and Stat5 tyrosine
phosphorylation in various cell types (24, 33), and Stat3 can bind to
the IRF-1 GAS in response to interleukin-6 stimulation (67). However,
no PRL-inducible Stat3 interaction can be detected at any of the known
PRL-inducible promoters (31, 33). Our studies show that Stat1 forms a
major complex at the IRF-1 GAS (33) and that Stat1 is a PRL-inducible
positive regulator of the IRF-1 promoter (Fig. 5
).
Recent studies have revealed novel properties of the Stat1 molecule
that may further elucidate its functions. Stat1
(91 kDa) is one of
the first Stat factors to be identified in the IFN-signaling pathway,
and it can be alternatively spliced to generate a carboxy
terminus-truncated, dominant negative Stat1ß (84 kDa) isoform (65).
Stat1 activation involves the tyrosine phosphorylation of Y701, which
is necessary for Stat1 homodimerization, nuclear translocation, and
DNA-binding activities (18, 65). In addition to tyrosine
phosphorylation, serine/threonine phosphorylation further enhances
Stat1 activation of target promoters (33, 68, 69). Recently, the
amino-terminal domain of Stat1 has been suggested to mediate
higher-order cooperative interactions of Stat1 dimers (70, 71).
Additionally, the first 63 a.a. of Stat1 may also be involved in
interaction with a protein tyrosine phosphatase, as its deletion
generated a mutant Stat1 protein with enhanced tyrosine
phosphorylation and DNA-binding activity (72, 73, 74). Therefore, both
amino and carboxy termini of Stat1 may be involved in complex formation
with other proteins, which either enhance or diminish Stat1
transactivation potentials. Some of these interacting proteins include
Stat2 and non-Stat proteins such as p48 to form the IFN
-inducible
ISGF3 complexes (75, 76) and other transcription factors such as IRF-1
(77, 78) and Sp1 (79). It is also possible that Stat1 activity may be
modulated by interaction with steroid hormones as has been shown for
Stat5a (80) and by the coactivator p300/CBP, which has been shown to
interact with both Stat1 (81, 82) and Stat2 (83). The ability of Stat1
to interact with a myriad of basal as well as inducible transcription
factors may explain our previous observation that only certain
anti-Stat1 antibodies were effective in supershift assays, as some
Stat1 epitopes may be blocked as a result of interaction with nearby
proteins (33). The potential interaction of Stat1 with some of these
factors highlights the complex regulatory controls involved in PRL- and
cell cycle-regulated transcription of the IRF-1 gene.
In summary, our studies show that Stat1 is a positive mediator of PRL
signaling to the IRF-1 promoter, and this activation requires the
PRM/Box 1, Y309, and Y382 residues in the PRL-R. These mutational
analyses, along with studies utilizing Stat1 (84, 85) and IRF-1 (86, 87) knock-out animals, should provide a wide basis from which to
address how PRL, through its activation of Stat1 and transcriptional
stimulation of IRF-1, plays a role in modulating various immune
responses (2, 88).
 |
MATERIALS AND METHODS
|
---|
Materials
Ovine PRL (oPRL-20) was obtained from Dr. P. Smith (National
Hormone and Pituitary Program/NIDDK, Baltimore, MD). Nb2 PRL-R Y309F
and Y382F mutant constructs (22) were obtained from Dr. P. A. Kelly
(INSERM, Paris, France). Anti-Stat1 (ISGF3 No. G16920) and anti-Stat3
(No. S21320) mAb were purchased from Transduction Laboratories
(Lexington, KY). Anti-pan Stat polyclonal antibodies (Ab), provided by
Dr. D. Levy (New York University, New York, NY), and DR1
oligonucleotides (oligos), provided from Dr. S. Tsai (Baylor College of
Medicine, Houston, TX), were previously described (33).
Wild Type and Mutant GAS Cloning
Three copies (3C) of wild type and mutant IRF-1 GAS oligo
flanked by 5'-XbaI and 3'-BamHI restriction sites
(lower case) were synthesized (Genosys, The Woodlands, TX).
The mutant GAS sequence was derived from EMSA studies as follows:
30 min PRL-treated Nb2 T cell extracts (33) were incubated with a wild
type GAS oligo probe, 5' CTGATTTCCCCGAAATGATG 3' (GAS core
underlined), and increasing concentrations of various mutant GAS
oligos as competitors (data not shown). The mutant GAS oligos,
each containing three mutations across the GAS core sequence, were
(mutations underlined): MutGAS1
5'-CTGACGACCCCGAAATGATG-3'; MutGAS2
5'-CTGATTTAGTCGAAATGATG-3'; MutGAS3
5'-CTGAATTCCCTACAATGATG-3'; and
MutGAS4 5'-CTGATTTCCCCGAGTCGATG-3'. Wild type
3C GAS sequences are:
5'-GCGtctagaCTGATTTCCCCGAAATGACTGATTTCCCCG-AAATGACTGATTTCCCCGAAATGAggatccGCG-3'
(GAS core underlined). Mutant 3C GAS sequences are:
5'-GCGtctagaTGACGATGTTAGCTTGACTGACGATGTTAGCTTGACTGATGACGAT-GTTAGCTggatccGCG
3' (mutations underlined; italicsdenote further changes to avoid generating potential binding
sites). Each 72-bp ds oligo was digested with XbaI and
BamHI, cloned into pBLCAT2, and tested for its ability to
respond to PRL stimulation by transfection.
GAS Mutations in the 1.7-kb IRF-1 Promoter
Site-directed mutations in the GAS element in the context of the
full-length 1.7-kb IRF-1 promoter were generated by overlap-extension
PCR (47). Oligos containing complementary 12-bp GAS mutations
(underlined) were: primer B:
5'-GAGCTAACATCGTCAGGCTGTTGTAGA-3' and primer C:
5'-CGATGTTAGCTCGATGAGGCGAAGTGG-3'.
Outside upstream primer A (-348/-334) and downstream primer D
(+21/+40) were derived from IRF-1 gene sequences (37, 40). PCR reaction
mixtures contained 1 µg of native 1.7-kb IRF-1 promoter DNA, 1.0
uM primers, 0.2 mM deoxynucleotide
triphosphates (Pharmacia, Piscataway, NJ), 1x Pfu reaction
buffer, and 2.5 U Pfu DNA polymerase (Clontech, La Jolla,
CA) to maximize replication fidelity. Conditions for AB and CD PCR
were: 94 C/1 min, 51 C/90 sec, 72 C/2 min with a 5-min extension (72 C)
at the end of 20 cycles. The first round of PCR generated 213 bp AB and
172 bp CD PCR products, which were combined with primers A and D for a
second round of PCR, using identical conditions except that a 52 C/90
sec annealing step and 25 cycles were used. The final 385-bp AD PCR
product contained a mutant GAS within the IRF-1 promoter sequences. The
AD fragment was gel purified, phosphorylated by T4 kinase (Promega,
Madison, WI), cloned into the EcoRV site in pBluescript
SKI(-), and sequenced by the dideoxy sequencing method (United States
Biochemical Corp., Cleveland, OH). The AD fragment was digested with
SacII and BglII to release the promoter-proximal
250-bp DNA, which was used to replace the corresponding wild type
sequences within the 1.7-kb IRF-1 promoter (deleted by a
SacII and BamHI digestion) in the pBLCAT3 vector
(40). This replacement generated a 1.7-kb IRF-1 promoter CAT construct
that contains a mutant GAS in the context of the 1.7-kb IRF-1
promoter.
PRM/Box 1 Mutations in the PRL-R
Overlap-extension PCR (47) was also used to generate two
pairwise alanine substitutions (underlined) in the PRM/Box 1
sequence of the Nb2 PRL-R. The mutant PRM/Box 1 primers are (replaced
codons underlined) (see also Fig. 2A
): FV primer B:
5'-AGCTGGTGGAGCGATGCAGGTCATCAT-3'; FV primer C:
5'-TGCATCGCTCCACCAGCTCCTGGGCCAAAA-3'; P1P2
primer B: 5'-AGCAACTGGTGCAAAGATGCAGGTCAT-3';
P1P2 primer C:
5'-ATCTTTGCACCAGTTGCTGG-GCCAAAA-3'; P2P3
primer B: 5'-TGCCCCAGCAACTGGTGGAAAGATGCA-3';
P2P3 primer C:
5'-CCAGTTGCTGGG-GCAAAAATAAAAGGA-3'. Upstream
outside primer A: 5'-GCCAGACCATGGATACTGG-3'; downstream outside
primerD: 5'-GTGGTCTGCTAGCAAATGTT-3'.
The PCR reaction mixtures contained 1 µg Nb2 PRL-R cDNA (14), 0.5
uM primers, 0.2 mM deoxynucleotide
triphosphates, 2.5 U Pfu DNA polymerase, and 1x
Pfu reaction buffer. PCR conditions were: 94 C/30 sec, 50
C/1 min, 72 C/90 sec with a 5-min extension (72 C) at the end for 30
cycles. The first round of PCR generated products AB (187, 190, and 196
bp for the FV, P1P2, and P2P3 mutants, respectively), and CD (551, 548
and 539 bp for the FV, P1P2, and P2P3 mutants, respectively). These
products were combined in a second round of PCR with primers A and D to
synthesize the full-length 720-bp product. The three PRM/Box 1 PCR
products were gel purified, digested with NcoI and
NheI, replaced into the wild type Nb2 PRL-R cDNA in the pECE
vector (14), and confirmed by DNA sequencing.
Stat1 Construct
Stat1
cDNA (69) was obtained from Drs. Z. Zhong and J.
Darnell (Rockefeller University, New York, NY). The 3.5-kb insert was
recloned into the pcDNA3 expression vector (pcDNA3-Stat1) (Invitrogen,
San Diego, CA) for high level expression in COS cells (27).
Whole Cell Protein Extracts of Transfected COS Cells
COS cells (2 x 106) were seeded in 100-mm
plates for transfection as described below. After 24 h, cells were
harvested and whole cell extracts were processed on ice. Briefly, three
packed cell volumes of extraction buffer (20 mM HEPES, pH
7.9, 20% glycerol, 0.55 M KCl, 0.2 mM EDTA,
1.5 mM MgCl2, and 2 mM
dithiothreitol plus protease and phosphatase inhibitors [0.5
mM phenylmethylsulfonyl fluoride, 1 mM
sodium orthovanadate, 2 µg/ml leupeptin, and 2 µg/ml aprotinin])
were added to cell pellets that were homogenized for 30 min on ice.
Whole cell extracts were harvested after centrifugation at 13,000 rpm
for 15 min at 4 C. Supernatant was dialyzed (dialysis buffer: 20
mM HEPES, pH 7.9, 20% glycerol, 0.1 M KCl, 0.2
mM EDTA, 5 mM MgCl2, 1
mM dithiothreitol, 0.5 mM phenylmethylsulfonyl
fluoride, 1 mM sodium vanadate) for 2 h. Dialyzed
samples were centrifuged again at 13,000 rpm for 15 min. Supernatant
was aliquoted and stored at -70 C until use.
EMSA
A 32-bp wild type IRF-1 GAS oligo was kinase-labeled with
32P-[ATP] (DuPont NEN, Boston, MA) as described
previously (33) and used as probe (3040,000 rpm, 0.10.5 ng) to
incubate with 4 µg nuclear extracts from Nb2 cells or 8 µg whole
cell extracts from transfected COS cells. For competition or antibody
supershift assays, cold oligos or antibodies were preincubated with
extracts for 20 min at 4 C before incubation with the labeled GAS probe
for another 20 min at room temperature as described (33). Samples were
loaded onto nondenaturing acrylamide (5%) gels and resolved by
electrophoresis using 0.25x Tris-borate-EDTA for 3 h as described
(33). Gels were dried and analyzed by auto-radiography.
Cell Culture, Transfection, and CAT Assays
Nb2 T lymphocytes were maintained in Fischers medium
(GIBCO/BRL, Grand Island, NY) supplemented with 10% newborn serum (JRH
BioSciences, Lenexa, KS), and 10% donor horse serum (HS) (JRH
BioSciences) as described (33). Cells were made quiescent in Fischers
medium containing 10% HS for 24 h before PRL stimulation (10
ng/ml), and nuclear extracts were prepared as described (33). COS-1
cells were maintained in DMEM (GIBCO/BRL) containing 10% fetal bovine
serum (FBS) (Atlanta Biologicals, Norcross, GA). For transfection,
1.5 x 105 COS cells were seeded per well in DMEM
containing 5% HS and allowed to remain overnight. Transfection was
performed by applying a mixture of 10 µl lipofectamine (GIBCO/BRL)
and 35 µg DNA prepared by using a Qiaprep column (Qiagen,
Chatsworth, CA) (see figure legends for DNA concentrations). Cells were
cultured in DMEM containing 1% HS for 2224 h in the presence or
absence of PRL (100 ng/ml) before harvesting. CMV-ß-gal was used for
normalization of transfection efficiency. Cell pellets were frozen and
thawed three times in 0.25 M Tris, pH 8.0. After 10 min
centrifugation at 14,000 rpm, the soluble fractions were collected for
ß-galactosidase and chloramphenicol acetyl transferase (CAT) assays
as described (40). After ß-galactosidase normalization, CAT assays
were performed for 13 h, and samples were separated by
chloroform-methanol (127:12) on TLC plates and scanned by the betascope
603 blot analyzer (Betagen, Mountain View, CA). All of the transfection
data were analyzed from at least three independent experiments and
plotted by StatMost program (DataMost Corporation, Salt Lake City, UT)
as percent CAT conversion ± SEM.
Anti-PRL-R Box 2 Polyclonal Antibodies
A synthetic 24 amino acid (a.a.) peptide corresponding to the
hydrophilic Box 2 region of the PRL-R
(Cys283-Glu-Asp-Leu-Leu-Val-Glu-Phe-Leu-Glu-Val-Asp-Asp-Asn-Glu-Asp-Arg-Leu-Met-Pro-Ser-His-Ser306)
(35, 48) was synthesized by an Applied Biosystems 430A Peptide
Synthesizer (Baylor College of Medicine, Houston, TX). The peptide was
conjugated to keyhole limpet hemocyanin as described (39). Polyclonal
anti-PRL-R peptide antibodies (Ab) (R123 Ab) were generated by
immunization of rabbits with 50 µg of conjugated peptide each for
four times. Ab titers were assessed by enzyme-linked immunosorbent
assay. Aliquots of serum were stored at -20 C until use.
Western Blot Analysis
The expression of PRL-R PRM/Box 1 mutants was examined by
Western blot analysis as described (33). The pelleted insoluble
fractions of PRL-R construct-transfected COS cells were resolved by
SDS-PAGE and transferred to immobilon-P membrane. The filter membrane
was blocked in 1% nonfat milk for 1 h, incubated with anti-PRL-R
Box 2 polyclonal Ab (1:400) for 3 h at room temperature, and
further incubated with donkey anti-rabbit IgG conjugated with
horseradish peroxidase (1:2000) for 1 h. After extensive washes,
the filter membrane was developed by chemiluminescent ECL as described
(Amersham, Arlington Heights, IL) (33).
 |
ACKNOWLEDGMENTS
|
---|
We thank Dr. Jeff Rosen for helpful discussions on the
manuscript, Dr. P. A. Kelly for PRL-R mutants, Drs. Z. Zhong and J.
Darnell for Stat1
cDNA, Dr. David Levy for anti-pan Stat antibodies,
Dr. S. Tsai for the DR1 oligonucleotides, and Ms. Lulu Lin for
technical assistance.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Dr. Li-yuan Yu-Lee, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030.
This work was supported in part by a NIH Training Grant T32-AI07495
(Y.-f. W.), by a National Institutes of Mental Health M.D./Ph.D.
Fellowship F30-MH10343 (K.D.O.) and by NIH Grant DK-44625 and American
Cancer Society Grant BE-49L (L.-y. Y.-L.).
Received for publication March 21, 1997.
Accepted for publication May 22, 1997.
 |
REFERENCES
|
---|
-
Nicoll CS, Bern HA 1972 On the action of prolactin among
the vertebrates: is there a common denominator? In: Wolstenholme GEN,
Knight J (eds) Lactogenic Hormones. Churchill Livingstone, London, pp
299324
-
Yu-Lee L-y. 1997 Molecular actions of prolactin in the immune
system. Proc Soc Exp Biol Med 215:118[Abstract]
-
Ben-Jonathan N, Mershon J, Allen D, Steinmetz R 1996 Extrapituitary prolactin: distribution, regulation, functions and
clinical aspects. Endocr Rev 17:639669[Medline]
-
Groner B, Gouilleux F 1995 Prolactin-mediated gene activation
in mammary epithelial cells. Curr Opin Genet Dev 5:587594[CrossRef][Medline]
-
Richards JS 1994 Hormonal control of gene expression in the
ovary. Endocr Rev 15:725751[Medline]
-
Gellersen B, Kempf R, Telgmann R, DiMattia GE 1994 Nonpituitary human prolactin gene transcription is independent of pit-1
and differentially controlled in lymphocytes and endometrial stroma.
Mol Endocrinol 8:356373[Abstract]
-
Nevalainen MT, Valve EM, Ingleton PM, Harkonen PL 1996 Expression and hormone regulation of prolactin receptors in rat dorsal
and lateral prostate. Endocrinology 137:30783088[Abstract]
-
LaVoie HA, Witorsch RJ 1995 Investigation of intracellular
signals mediating the anti-apoptotic action of prolactin in Nb2
lymphoma cells. Proc Soc Exp Biol Med 209:257269[Abstract]
-
McAveney KM, Gimble JM, Yu-Lee L-y. 1996 Prolactin receptor
expression during adipocyte differentiation of bone marrow stroma.
Endocrinology 137:57235726[Abstract]
-
Bazan JF 1990 Structural design and molecular evolution of a
cytokine receptor superfamily. Proc Natl Acad Sci USA 87:69346938[Abstract]
-
Cosman D 1993 The hematopoietin receptor superfamily. Cytokine 5:95106[Medline]
-
Davis JA, Linzer DIH 1989 Expression of multiple forms of the
prolactin receptor in mouse liver. Mol Endocrinol 3:674680[Abstract]
-
Ali S, Pellegrini I, Kelly PA 1991 A prolactin-dependent
immune cell line (Nb2) expresses a mutant form of prolactin receptor.
J Biol Chem 266:2011020117[Abstract/Free Full Text]
-
ONeal KD, Yu-Lee L-y. 1994 Differential signal transduction
of the short, Nb2, and long PRL receptor: activation of IRF-1 and cell
proliferation. J Biol Chem 269:2607626082[Abstract/Free Full Text]
-
Lesueur L, Edery M, Ali S, Paly J, Kelly PA, Djiane J 1991 Comparison of long and short forms of the prolactin receptor on
prolactin-induced milk protein gene transcription. Proc Natl Acad Sci 88:824828[Abstract]
-
Ali S, Edery M, Pellegrini I, Lesueur L, Paly J, Djiane J,
Kelly PA 1992 The Nb2 form of prolactin receptor is able to activate a
milk protein gene promoter. Mol Endocrinol 6:12421248[Abstract]
-
Das R, Vonderhaar BK 1995 Transduction of prolactins (PRL)
growth signal through both long and short forms of the PRL receptor.
Mol Endocrinol 9:17501759[Abstract]
-
Schindler C, Darnell Jr JE 1995 Transcriptional responses to
polypeptide ligands: the Jak-STAT pathway. Annu Rev Biochem 64:621651[CrossRef][Medline]
-
Kelly PA, Edery M, Finidori J, Postel-Vinay M, Gougon L, Ali
S, Dinerstein H, Sotiropoulos A, Lochnan H, Ferrag F, et al. 1994 Receptor domains involved in signal transduction of prolactin and
growth hormone. Proc Soc Exp Biol Med 206:280283[Abstract]
-
Rui H, Lebrun J-J, Kirken RA, Kelly PA, Farrar WL 1994 JAK2
activation and cell proliferation induced by antibody-mediated
prolactin receptor dimerization. Endocrinology 135:12991306[Abstract]
-
Chang W-P, Clevenger CV 1996 Modulation of growth factor
receptor function by isoform heterodimerization. Proc Natl Acad Sci USA 93:59475952[Abstract/Free Full Text]
-
Lebrun J, Suhad A, Goffin V, Ullrich A, Kelly PA 1995 A single
phosphotyrosine residue of the prolactin receptor is responsible for
activation of gene transcription. Proc Natl Acad Sci USA 92:40314035[Abstract/Free Full Text]
-
Hunter T 1995 Protein kinases and phosphatases: the yin and
yang of protein phosphorylation and signaling. Cell 80:225236[Medline]
-
DaSilva L, Rui H, Erwin RA, Howard OMZ, Kriken RA, Malabarba
MG, Hackett RH, Larner AC, Farrar WL 1996 Prolactin recruits Stat1,
Stat3, and Stat5 independent of conserved receptor tyrosines Tyr402,
Tyr479,Tyr515 and Tyr 580. Mol Cell Endocrinol 117:131140[CrossRef][Medline]
-
Kazansky AV, Raught B, Lindsey SM, Wang Y-f, Rosen JM 1995 Regulation of MGF/STAT5a during mammary gland development. Mol
Endocrinol 9:15981609[Abstract]
-
Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L 1995 Cloning and expression of Stat5 and an additional homologue
(Stat5b) involved in prolactin signal transduction in mouse mammary
tissue. Proc Natl Acad Sci USA 92:88318835[Abstract]
-
Luo G, Yu-Lee L-y 1997 Transcriptional inhibition by Stat5:
differential activities at growth-related vs.
differentiation-specific promoters. J Biol Chem, in press
-
Gouilleux F, Wakao H, Mundt M, Groner B 1994 Prolactin induces
phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA
binding and induction of transcription. EMBO J 13:43614369[Abstract]
-
Burdon TG, Demmer J, Clark JA, Watson CJ 1994 The mammary
factor MPBF is a prolactin-induced transcriptional regulator which
binds to STAT factor recognition sites. Fed Eur Biochem Soc 350:177182
-
Li S, Rosen JM 1995 CTF/NF1 and mammary gland factor (Stat5)
play a critical role in regulating rat whey acidic protein gene
expression in transgenic mice. Mol Cell Biol 15:20632070[Abstract]
-
Russell DL, Norman RL, Dajee M, Liu X, Hennighausen L,
Richards JS 1996 Prolactin-induced activation and binding of Stat
proteins to the IL-GRE of the
2-macroglobulin (
2M) promoter:
relation to the expression of
2M in the rat ovary. Biol Reprod 55:10291038[Abstract]
-
Stevens AM, Wang Y-f, Sieger KA, Lu H-f, Yu-Lee L-y. 1995 Biphasic transcriptional regulation of the interferon regulatory
factor-1 gene by prolactin: involvement of gamma-interferon activated
sequence and Stat-related proteins. Mol Endocrinol 9:513525[Abstract]
-
Wang Y-f, Yu-Lee L-y. 1996 Multiple Stat complexes interact at
the IRF-1 GAS in prolactin-stimulated Nb2 T cells. Mol Cell Endocrinol 121:1928[CrossRef][Medline]
-
ONeal KD, Yu-Lee L-y. 1993 The proline-rich motif (PRM): a
novel feature of the cytokine/hematopoietin receptor superfamily. Lymph
Cytokine Res 12:309312
-
DaSilva L, Howard OMZ, Rui H, Kirken RA, Farrar WL 1994 Growth
signaling and JAK2 association mediated by membrane-proximal
cytoplasmic regions of prolactin receptors. J Biol Chem 269:1826718270[Abstract/Free Full Text]
-
Lebrun J, Ali S, Ullrich A, Kelly PA 1995 Proline-rich
sequence-mediated Jak2 association to the prolactin receptor is
required but not sufficient for signal transduction. J Biol Chem 270:1066410670[Abstract/Free Full Text]
-
Yu-Lee L-y, Hrachovy JA, Stevens AM, Schwarz LA 1990 Interferon-regulatory factor 1 is an immediate-early gene under
transcriptional regulation by prolactin in Nb2 T cells. Mol Cell Biol 10:30873094[Medline]
-
Schwarz LA, Stevens AM, Hrachovy JA, Yu-Lee L-y. 1992 Interferon regulatory factor-1 is inducible by prolactin, interleukin-2
and concanavalin A in T cells. Mol Cell Endocrinol 86:103110[CrossRef][Medline]
-
Stevens AM, Yu-Lee L-y. 1992 The transcription factor
interferon regulatory factor-1 is expressed during both early G1 and
the G1/S transition in the prolactin-induced lymphocyte cell cycle. Mol
Endocrinol 6:22362243[Abstract]
-
Stevens AM, Yu-Lee L-y. 1994 Multiple prolactin-responsive
elements mediate G1 and S phase expression of the interferon regulatory
factor-1 gene. Mol Endocrinol 8:345355[Abstract]
-
David M, Petricoin EF, III, Igarashi K-I, Feldman GM, Finbloom
DS, Larner AC 1994 Prolactin activates the interferon-regulated p91
transcription factor and the Jak2 kinase by tyrosine phosphorylation.
Proc Natl Acad Sci USA 91:71747178[Abstract]
-
Gilmour KC, Reich NC 1994 Receptor to nucleus signaling by
prolactin and interleukin 2 via activation of latent DNA-binding
factors. Proc Natl Acad Sci USA 91:68506854[Abstract]
-
Gouilleux F, Mortiz D, Humar M, Moriggl R, Berchtold S, Groner
B 1995 Prolactin and interleukin-2 receptors in T lymphocytes signal
through a MGF-Stat5-like transcription factor. Endocrinology 136:57005708[Abstract]
-
Wakao H, Gouilleux F, Groner B 1994 Mammary gland factor (MGF)
is a novel member of the cytokine regulated transcription factor gene
family and confers the prolactin response. EMBO J 13:21822191[Abstract]
-
Luckow B, Schutz G 1987 CAT constructions with multiple unique
restriction sites for the functional analysis of eukaryotic promoters
and regulatory elements. Nucleic Acids Res 15:5490[Medline]
-
Moriggl R, Fouilleux-Gruart V, Jahne R, Berchtold S, Gartmann
C, Liu X, Hennighausen L, Sotiropoulos A, Groner B, Gouilleux F 1996 Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5
results in sustained DNA binding and a dominant negative phenotype. Mol
Cell Biol 16:56915700[Abstract]
-
Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR 1989 Site-directed mutagenesis by overlap extension using polymerase chain
reaction. Gene 77:5159[CrossRef][Medline]
-
Edery M, Levi-Meyrueis C, Paly J, Kelly PA, Djian J 1994 A
limited cytoplasmic region of the prolactin receptor critical for
signal transduction. Mol Cell Endocrinol 102:3944[CrossRef][Medline]
-
Raz R, Durbin JE, Levy DE 1994 Acute phase response factor and
additional members of the interferon-stimulated gene factor 3 family
integrate diverse signals from cytokines, interferons, and growth
factors. J Biol Chem 269:2439124395[Abstract/Free Full Text]
-
Sims SH, Cha Y, Romine MF, Gao P-Q, Gottlieb K, Deisseroth AB 1993 A novel interferon-inducible domain: structural and functional
analysis of the human interferon regulatory factor 1 gene promoter. Mol
Cell Biol 13:690702[Abstract]
-
Kanno Y, Kozak CA, Schindler C, Driggers PH, Ennist DL,
Gleason SL, Darnell Jr JE, Ozato K 1993 The genomic structure of the
murine ICSBP gene reveals the presence of the gamma
interferon-responsive element, to which an ISGFalpha subunit (or
similar) molecule binds. Mol Cell Biol 13:39513963[Abstract]
-
ONeal KD, Yu-Lee L-y, Shearer WT 1995 The proline-rich motif
is necessary but not sufficient for prolactin receptor signal
transduction. Ann NY Acad Sci 766:282284[Medline]
-
ONeal KD, Chari MV, McDonald CH, Cook RG, Yu-Lee L-y,
Morrisett JD, Shearer WT 1996 Multiple cis-trans conformers
of the prolactin receptor proline-rich motif (PRM) peptide detected by
reverse-phase HPLC, CD and NMR spectroscopy. Biochem J 315:833844[Medline]
-
Smit LS, Meyer DJ, Billestrup N, Norstedt G, Schwartz J,
Carter-Su C 1996 The role of the growth hormone (GH) receptor and Jak1
and Jak2 kinases in the activation of Stats1, 3, and 5 by GH. Mol
Endocrinol 10:519533[Abstract]
-
Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE,
Yancopoulos GD 1995 Choice of STATs and other substrates specified by
modular tyrosine-based motifs in cytokine receptors. Science 267:13491353[Medline]
-
Greenlund AC, Farrar MA, Viviano BL, Schreiber RD 1994 Ligand-induced IFN-gamma receptor tyrosine phosphorylation couples the
receptor to its signal transduction system (p91). EMBO J 13:15911600[Abstract]
-
Gerhartz C, Heesel B, Sasse J, Hemmann U, Landgraf C,
Schneider-Mergener J, Horn F, Heinrich P, C, Graeve L 1996 Differential
activation of acute phase response factor/Stat3 and Stat1 via the
cytoplasmic domain of the interleukin 6 signal transducer gp130. I.
Definition of a novel phosphotyrosine motif mediating Stat1 activation.
J Biol Chem 271:1299112998[Abstract/Free Full Text]
-
Wang Y-D, Wong K, Wood WI 1995 Intracellular tyrosine residues
of the human growth hormone receptor are not required for the signaling
of proliferation or JAK-Stat activation. J Biol Chem 270:70217024[Abstract/Free Full Text]
-
Lobie PE, Allevato G, Nielsen JH, Norstedt G, Billestrup N 1995 Requirement of tyrosine residues 333 and 338 of the growth hormone
(GH) receptor for selected GH-stimulated function. J Biol Chem 270:2174521750[Abstract/Free Full Text]
-
Yi W, Kim S-O, Jiang J, Park S-H, Kraft AS, Waxman DJ, Frank
SJ 1996 Growth hormone receptor cytoplasmic domain differentially
promotes tyrosine phosphorylation of signal transducers and activators
of transcription 5b and 3 by activated JAK2 kinase. Mol Endocrinol 10:14251443[Abstract]
-
Fujitani Y, Hibit M, Fukada T, Takahashi-Tezuka M, Yoshida
H, Yamaguchi T, Sugiyama K, Yamanaka Y, Nakajima K, Hirano T 1997 An
alternative pathway for STAT activation that is mediated by the direct
interaction between JAK and STAT. Oncogene 751761
-
Fukunaga R, Ishizaka-Ikeda E, Nagata S 1993 Growth and
differentiation signals mediated by different regions in the
cytoplasmic domain of granulocyte colony-stimulating factor receptor.
Cell 74:10791087[Medline]
-
Miyazaki T, Liu Z-J, Kawahara A, Minami Y, Yamada K, Tsujimoto
Y, Barsoumian EL, Perlmutter RM, Taniguchi T 1995 Three distinct IL-2
signaling pathways mediated by bcl-2, c-myc, and lck cooperate in
hematopoietic cell proliferation. Cell 81:223231[Medline]
-
Liu X, Robinson GW, Hennighausen L 1996 Activation of Stat5a
and Stat5b by tyrosine phosphorylation is tightly linked to mammary
gland differentiation. Mol Endocrinol 10:14961506[Abstract]
-
Shuai K, Stark GR, Kerr IM, Darnell Jr JE 1993 A single
phosphotyrosine residue of Stat91 required for gene activation by
interferon-gamma. Science 261:17441746[Medline]
-
Onate SA, Tsai SY, Tsai MJ, OMalley BW 1995 Sequence and
characterization of a coactivator for the steroid hormone receptor
superfamily. Science 270:13541357[Abstract]
-
Harroch S, Revel M, Chebath J 1994 Interleukin-6 signaling via
four transcription factors binding palindromic enhancers of different
genes. J Biol Chem 269:2619126195[Abstract/Free Full Text]
-
Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S 1995 Requirement of serine phosphorylation for formation of STAT-promoter
complexes. Science 267:19901994[Medline]
-
Wen ZL, Zhong Z, Darnell JE 1995 Maximal activation of
transcription by Stat1 and Stat3 requires both tyrosine and serine
phosphorylation. Cell 82:241250[Medline]
-
Xu X, Sun Y-L, Hoey T 1996 Cooperative DNA binding and
sequence-selective recognition conferred by the Stat amino-terminal
domain. Science 273:794797[Abstract]
-
Vinkemeier U, Cohen SL, Moarefi I, Chait BT, Kuriyan H,
Darnell Jr JE 1996 DNA binding of in vitro activated
Stat1
, Stat1ß and truncated Stat1: interaction between
NH2-terminal domains stabilizes binding of two dimers to tandem DNA
sites. EMBO J 15:56165626[Abstract]
-
Shuai K, Liao J, Song MM 1996 Enhancement of antiproliferative
activity of gamma interferon by the specific inhibition of tyrosine
dephosphorylation of Stat1. Mol Cell Biol 16:49324941[Abstract]
-
Haspel RL, Salditt-Georgieff M, Darnell Jr JE 1996 The rapid
inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a
protein tyrosine phosphatase. EMBO J 15:62626268[Abstract]
-
Haque SJ, Flati V, Deb A, Williams BRG 1995 Role of
protein-tyrosine phosphatases in Stat1
-mediated cell signaling.
J Biol Chem 270:2570925714[Abstract/Free Full Text]
-
Li X, Leung S, Qureshi S, Darnell Jr JE, Stark GR 1996 Formation of Stat1-Stat2 heterodimers and their role in the activation
of IRF-1 gene transcription by interferon-alpha. J Biol Chem 271:57905794[Abstract/Free Full Text]
-
Horvath CM, Stark GR, Kerr IM, Darnell Jr JE 1996 Interactions
between STAT and non-STAT proteins in the interferon-stimulated gene
factor 3 transcription complex. Mol Cell Biol 16:69576964[Abstract]
-
Harroch S, Gothelf Y, Revel M, Chebath J 1995 5' upstream
sequences of MyD88, an IL-6 primary response gene in M1 cells:
detection of functional IRF-1 and Stat factors binding sites. Nucleic
Acids Res 23:35393546[Abstract]
-
Briken V, Ruffner H, Schultz U, Schwartz A, Reis LFL, Strehlow
I, Decker T, Staeheli P 1995 Interferon regulatory factor 1 is required
for mouse Gbp gene activation by gamma interferon. Mol Cell Biol 15:975982[Abstract]
-
Look DC, Pelletier MR, Tidwell RM, Roswit WT, Holtzman MJ 1995 Stat1 depends on transcriptional synergy with Sp1. J Biol Chem 270:3026430267[Abstract/Free Full Text]
-
Stocklin E, Wissler M, Gouilleux F, Groner B 1996 Functional
interactions between Stat5 and the glucocorticoid receptor. Nature 383:726728[CrossRef][Medline]
-
Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM,
Darnell Jr JE 1996 Two contact regions between Stat1 and CBP/p300 in
interferon gamma signaling. Proc Natl Acad Sci USA 93:1509215096[Abstract/Free Full Text]
-
Horvai A, Xu L, Korzus E, Brard G, Kalafus D, Mullen T-M, Rose
DW, Rosenfeld MG, Glass CK 1997 Nuclear integration of Jak/Stat and
Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci USA 94:10741079[Abstract/Free Full Text]
-
Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z,
DAndrea A, Livingston DM 1996 Cooperation of Stat2 and p300/CBP in
signalling induced by interferon-
. Nature 383:344347[CrossRef][Medline]
-
Meraz MA, White JM, Sheehan KCF, Bach EA, Rodig SJ, Dighe AS,
Kaplan DH, Riley JK, Greenlund AC, Campbell D, et al. 1996 Targeted
disruption of the Stat1 gene in mice reveals unexpected
physiologic specificity in the JAK-STAT signaling pathway. Cell 84:431442[Medline]
-
Durbin JE, Hackenmiller R, Simon MC, Levy DE 1996 Targeted
disruption of the mouse Stat1 gene results in compromised
innate immunity to viral disease. Cell 84:443450[Medline]
-
Ruffner H, Reis LF, Naf D, Weissmann C 1993 Induction of type
I interferon genes and interferon-inducible genes in embryonal stem
cells devoid of interferon regulatory factor-1. Proc Natl Acad Sci USA 90:1150311507[Abstract]
-
Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T,
Watanabe N, Kundig TM, Amakawa R, Kishihara K, Wakeham A, et al. 1993 Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN
gene induction and aberrant lymphocyte development. Cell 75:8397[Medline]
-
White LC, Wright KL, Felix NJ, Ruffner H, Reis LFL, Pine R,
Ting JP-Y 1996 Regulation of LMP2 and TAP1 genes by IRF-1 explains the
paucity of CD8+ T cells in IRF-1-/- mice. Immunity 5:365376[Medline]